Spots Global Cancer Trial Database for ra
Every month we try and update this database with for ra cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
Hepatocellular Carcinoma and Rheumatoid Arthritis | NCT02880306 | Carcinoma, Hepa... | RA | 18 Years - 99 Years | Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation | |
Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Anti-Tumor Necrosis Factor α (Anti-TNFα) Agents (CAIN457F2309 and CAIN457F2309E1) | NCT01350804 | Rheumatoid Arth... | AIN457 Placebo Abatacept | 18 Years - | Novartis | |
A Phase I, Open-Label, Dose-Escalation Study of CC-11006 In Subjects With Low- or Intermediate-1 Risk Myelodysplastic Syndromes | NCT00458159 | Myelodysplastic... | CC-11006 | 18 Years - | Celgene | |
Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Anti-Tumor Necrosis Factor α (Anti-TNFα) Agents (CAIN457F2309 and CAIN457F2309E1) | NCT01350804 | Rheumatoid Arth... | AIN457 Placebo Abatacept | 18 Years - | Novartis | |
Hepatocellular Carcinoma and Rheumatoid Arthritis | NCT02880306 | Carcinoma, Hepa... | RA | 18 Years - 99 Years | Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation | |
A Phase I, Open-Label, Dose-Escalation Study of CC-11006 In Subjects With Low- or Intermediate-1 Risk Myelodysplastic Syndromes | NCT00458159 | Myelodysplastic... | CC-11006 | 18 Years - | Celgene | |
Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Anti-Tumor Necrosis Factor α (Anti-TNFα) Agents (CAIN457F2309 and CAIN457F2309E1) | NCT01350804 | Rheumatoid Arth... | AIN457 Placebo Abatacept | 18 Years - | Novartis |